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Background: It is uncertain whether the extra acquisition costs of atypical antipsychotics over typical antipsychotics
are offset by their other reduced resource use especially in hospital services in China. This study compared the
psychiatric-related health care resource utilization and direct medical costs for patients with schizophrenia initiating
atypical or typical antipsychotics in Tianjin, China.
Methods: Data were obtained from the Tianjin Urban Employee Basic Medical Insurance database (2008–2010). Adult
patients with schizophrenia with ≥1 prescription for antipsychotics after ≥90-day washout and 12-month continuous
enrollment after first prescription was included. Psychiatric-related resource utilization and direct medical costs of the
atypical and typical cohorts were estimated during the 12-month follow-up period. Logistic regressions, ordinary least
square (OLS), and generalized linear models (GLM) were employed to estimate differences of resource utilization and
costs between the two cohorts. One-to-one propensity score matching was conducted as a sensitivity analysis.
Results: 1131 patients initiating either atypical (N = 648) or typical antipsychotics (N = 483) were identified. Compared
with the typical cohort, the atypical cohort had a lower likelihood of hospitalization (45.8% vs. 56.7%, P < 0.001; adjusted
OR: 0.58, P < 0.001) over the follow-up period. Medication costs for the atypical cohort were higher than the typical cohort
($438 vs. $187, P < 0.001); however, their non-medication medical costs were significantly lower ($1223 vs. $1704, P < 0.001).
The total direct medical costs were similar between the atypical and typical cohorts before ($1661 vs. $1892, P = 0.100) and
after matching ($1711 vs. 1868, P = 0.341), consistent with the results from OLS and GLM models for matched cohorts.
Conclusions: The atypical cohort had similar total direct medical costs compared to the typical cohort. Higher medication
costs associated with atypical antipsychotics were offset by a reduction in non-medication medical costs, driven by fewer
hospitalizations.
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Schizophrenia is a complex neurobehavioral disorder that
adversely affects a broad range of psychological functions
including thinking, perception, ideation, concentration,
motivation, and judgment [1,2]. It affects approximately
1% of the population worldwide [3], and the prevalence in
China was estimated at 0.78% during 2001 to 2005 [4].* Correspondence: jingwu@tju.edu.cn
1School of Pharmaceutical Science and Technology, Tianjin University, No 92
Weijin Road, Nankai District, Tianjin, China
Full list of author information is available at the end of the article
© 2015 He et al.; licensee BioMed Central. This
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Despite its relatively low prevalence compared to some
other chronic diseases, schizophrenia imposes a significant
burden on patients and their families due to its early age
of onset, debilitating symptoms, and frequent relapses
[5,6]. The economic burden of schizophrenia can be
broadly divided into direct costs and indirect costs. Direct
health care costs associated with the care of patients with
schizophrenia, including the costs of medications, hospi-
talizations, diagnostic tests and medical procedures, and
long-term care services have been reported to range from
1.5% to 3% of the total national health care expenditure inis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ect costs, related to lost productivity due to unemploy-
ment, absence from work, and premature mortality have
been estimated to be even greater than direct costs in
many countries [8,9]. Consistent with studies from west-
ern countries, a regional study in China suggested that the
economic burden for Chinese patients with schizophrenia
was also considerable ($2586 per patient-year), of which
66% was due to indirect costs [10].
A cure for schizophrenia has not yet been found, but
most patients’ symptoms can be improved with pharma-
cotherapy. Antipsychotic medications are the main stay
of treatment used to manage acute psychotic exacerbations
and as maintenance therapy to prevent relapse among
patients with schizophrenia [11]. The first-generation anti-
psychotic medications, also called typical antipsychotics,
were introduced in the 1950s. They not only provided
therapeutic benefit for patients with schizophrenia but also
carried the risk of important adverse events including
extrapyramidal symptoms [12]. The introduction of the
second-generation (so called atypical) antipsychotics, in the
1990s, was viewed as an improvement over the existing
pharmacological options. Evidence from the literature has
shown that atypical antipsychotics (including clozapine,
olanzapine, and risperidone) are more efficacious for both
positive and negative symptoms, and are associated with
fewer extrapyramidal side-effects than typical antipsy-
chotics; however, they are associated with greater increases
in body weight and other metabolic parameters [13,14].
The atypical antipsychotics are generally recommended as
first-line therapies in the clinical guidelines of many coun-
tries including China [1,2,14].
However, the utilization of branded atypical antipsy-
chotics may have been restricted in the years following
their launch due to the higher daily acquisition costs,
compared to the typical antipsychotics, which are avail-
able as generic formulations [15]. Some studies have
shown that the additional medication costs of the newer
atypical drugs may be offset by reductions in other types
of health care spending, which is known as the offset hy-
pothesis [16]. It assumes that, in terms of antipsychotics,
patients using atypical medications may have improved
medication adherence and reduced rates of relapse,
which are associated with intense use of health care
resources, relative to typical medications. This can result
in reductions in the use of other medical services such
as hospitalizations and acute care facilities [17,18]. There
is still a debate about whether the lower subsequent
non-medication medical costs associated with the use of
atypical antipsychotics are sufficiently large as to offset
their greater upfront medication costs [19-21].
The present study was therefore carried out to evalu-
ate the health service utilization and costs of treatment
initiation with atypical antipsychotics in patients withschizophrenia in comparison with typical antipsychotics,
as prescribed in the context of routine clinical practice
using real-world claims data in China. The first objective
was to explore whether initiation with atypical medications
was associated with better treatment outcomes compared
with typical medications, as measured by better medica-
tion adherence and reduced rates of hospitalization. Sec-
ondly, the study aimed to explore whether atypical
initiators had lower non-medication related medical costs,
and if they did, whether the reductions were enough to
offset their higher medication costs — in other words,
whether atypical antipsychotics represented a cost-
effective alternative to typical antipsychotics, based on the
principle that a better outcome was achieved for a similar
or lower total cost.
Methods
Data source
This retrospective study used the Urban Employee Basic
Medical Insurance (UEBMI) Claims of Tianjin from
2008 through 2010, which was obtained from the Tianjin
Municipal Human Resources and Social Security Bureau
through a formal request for research purposes. The
UEBMI system, which is one of three basic medical
insurance systems in China, was established in 1998 and
covers employees and retirees in both the public and
private sectors. The enrollees of the UEBMI in Tianjin
included almost 5.1 million unique members by 2010,
representing 51.7% of the registered residences in Tian-
jin city [22]. The analytical sample in this study was a
random sample of 30% of all enrollees in the Tianjin
UEBMI. With the establishment of the electronic out-
patient records in 2008, the UEBMI database used in the
present study included all inpatient, outpatient and pre-
scription claims of the enrollees. This database provided
patient-level demographic information combined with
all the data relating to itemized medical service items
and costs. Specifically, inpatient and outpatient service
claims included type of service, date of service, units
(days) of service, amount billed, and amount paid. Pre-
scription drug claims identified the specific product dis-
pensed, quantity, strength, the date the prescription was
filled, and the associated drug acquisition cost. As the
analysis for this study was carried out on an anonymized
database, ethical approval was not required.
Study sample
Adult patients (≥18 years of age) who had a schizophre-
nia-relevant diagnosis (ICD-10 code F20 supplemented by
the Chinese description) and an initial prescription for an
antipsychotic between April 1, 2008 and December 31,
2009 were included. The antipsychotic medications
investigated in the present study comprised all the
typical (chlorpromazine, perphenazine, fluphenazine,
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penfluridol) and atypical antipsychotics (clozapine, olanza-
pine, quetiapine, risperidone) reimbursed by UEBMI. The
index date was defined as the date of patients’ first pre-
scriptions following a 90-day washout period during
which patients did not receive any antipsychotics. Atypical
and typical cohorts were defined according to patients’
initial prescription regardless of their subsequent switch-
ing patterns. Patients who received both atypical and typ-
ical drugs at the index date or who were not continuously
insured for 3 months before (baseline period) or for
12 months after the index date (follow-up period) were
excluded.Measures
Psychiatric-related health care resource utilization and
direct medical costs for the 12-month follow-up period
were estimated. Medical claims under the primary diag-
nosis of ICD-10 of F00-F99 (supplemented by Chinese
description) were identified as psychiatric related. Phar-
macy resource utilization included the use of any antipsy-
chotics and concomitant medications including anxiolytics,
anticholinergics, antidepressants, sedative-hypnotics medi-
cations, and mood stabilizers. Adherence was assessed by
measuring the days on antipsychotics, which were the total
number of non-overlapped days covered by antipsychotics
during follow-up period. Persistence with antipsychotics
was defined as the time to discontinuation for any cause
and calculated as the number of consecutive days from the
index date to the first medication gap of >30 days [23].
Medical claims of psychiatric-related hospitalizations and
outpatient visits were estimated as medical resource
utilization. Among medical resource users, the number of
hospitalizations, length of stay per hospital admission, and
the number of outpatient visits were analyzed.
Psychiatric-related costs were calculated from the
payer’s perspective including the payment paid by the in-
surance and the patients. Direct medical costs were calcu-
lated as the sum of medication costs and non-medication
medical costs. Medication costs were composed of anti-
psychotic medications, concomitant medications, and
other medications. Non-medication medical costs corre-
sponded to the use of any other health care services
except medications, including the costs of both inpatient
and outpatient services. The costs of inpatient services
were further broken down into non-medication treatment
costs, laboratory and diagnostic costs, and the costs of
other medical services. Specifically, non-medication treat-
ment costs corresponded to the costs of any other treat-
ment except medications, which included nursing,
monitoring, psychotherapy, behavioral training and inter-
vention, etc. Laboratory and diagnostic costs referred to the
costs of physical examinations and biochemical tests. Costsof other medical services included blood transfusions,
medical consumables, air conditioning and heating fees.
Statistical analysis
Descriptive analyses were undertaken to evaluate differ-
ences in baseline characteristics and outcomes between
the atypical and typical cohorts. Group comparisons
were performed using two-sample t-tests for continuous
variables, and chi-square tests or Fisher’s exact tests for
categorical variables.
Multiple regression procedures were further employed
to test for differences of resource utilization and costs
between the two cohorts. Logistic regression models
predicting the presence of any medical or concomitant
pharmacy utilization in the follow-up year were devel-
oped. Ordinary least square (OLS) models and general-
ized linear models (GLM) with a log link and a negative
binomial distribution were both used to estimate the
differences in total costs and cost components. Negative
binomial distribution was employed to take into account
the over-dispersion of the cost data. Modified Park tests
indicated that this specification was adequate relative to
other types of distributions such as the Gamma or Poisson
distribution [24]. The incremental effects between two
cohorts in GLM models were obtained using the
method of recycled predictions [25].
All regression models adjusted for patient characteristics
and indicators of disease complexity at baseline. Specific-
ally, the following types of patient-level variables were
used as control variables in each model: demographics
(age, gender, and working/retired), mental comorbidities
(depression, anxiety, sleep disorder, and other mental
diseases), concomitant medications (anxiolytics, anti-
cholinergics, antidepressants, sedative-hypnotics, and
mood stabilizers), mean number of psychiatric-related
hospitalizations and outpatient visits and the total
psychiatric-related direct medical costs during the prior
3 months.
Statistical analyses were conducted using STATA 12.0.
A P-value of <0.05 was considered as statistically significant.
All costs were converted to USD with an exchange rate in
2009 (6.83 CNY equal to 1 USD).
Sensitivity analysis
In observational studies, selection bias can be a potential
limitation in evaluating the outcomes of alternative in-
terventions because patients are not randomly assigned
to different therapies. Accordingly, a sensitivity analysis
using propensity-score matching, which can control
observable selection bias and render the two treatment
cohorts more comparable, was conducted to test the
robustness of the estimated outcomes. In the current
study, the propensity score is a subject’s probability of
receiving atypical antipsychotics on the observed
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sion which controlled for all independent variables in
multivariate analyses. A greedy, one-to-one matching
algorithm without replacement was employed to form
pairs of atypical and typical cohorts. With the non-
replacement technique, when an atypical patient is
matched to a typical patient, both cases are removed
from the pool. The caliper width was narrowed down
progressively from 0.2*δ (0.2 of the standard deviation of
the estimated propensity score) until all the baseline
variables appeared with no significant differences [26].
Outcomes of matched pairs were compared using paired
t tests for continuous variables, and McNemar’s tests for
categorical variables. Standardized differences, which are
independent of sample size, were also estimated to com-










Mean age (in years)
[Mean(SD)]
51.3 (13.0) 52.6 (11.9) 0.081 −0.1
Female [n(%)] 357 (55.1%) 267 (55.3%) 0.950 −0.00
Retired [n(%)] 338 (52.2%) 282 (58.4%) 0.037 −0.1
Concomitant
medications [n(%)]
Anxiolytics 74 (11.4%) 57 (11.8%) 0.843 −0.01
Anticholinergics 28 (4.3%) 15 (3.1%) 0.290 0.064
Antidepressants 24 (3.7%) 22 (4.6%) 0.473 −0.04
Sedative-hypnotics 9 (1.4%) 17 (3.5%) 0.018 −0.1
Mood stabilizers 7 (1.1%) 6 (1.2%) 0.787 −0.01
Mental comorbidities
[n(%)]
Sleep disorder 38 (5.9%) 29 (6.0%) 0.921 −0.00
Depression 15 (2.3%) 16 (3.3%) 0.309 −0.06
Anxiety disorder 8 (1.2%) 9 (1.9%) 0.462 −0.05
Other psychotic
disorder#
6 (0.9%) 3 (0.6%) 0.740 0.035




0.02 (0.15) 0.05 (0.25) 0.028 −0.1
Mean number of
outpatient visits
0.17 (0.58) 0.22 (0.83) 0.332 −0.06
Direct medical cost ($)
[Mean(SD)]
20 (124) 42 (200) 0.027 −0.1
Continuous variables were compared using two-sample t-tests for unmatched samples
using chi-square tests or Fisher's exact tests for unmatched samples and McNemar’s te
statistical significance.
# Other psychotic disorder corresponded to any other mental disorders (ICD-10 F00
mania, bipolar disorder, schizoaffective disorders, disorders of adult personality andthe matched sample with those in the unmatched sam-
ple, and the imbalance defined as absolute value >0.1
[27]. Logistic regressions for resource utilization, OLS
and GLM models for cost differences were also con-
ducted for matched sample.
Results
Baseline characteristics
A total of 1131 patients who initiated therapy with atyp-
ical (N = 648) or typical (N = 483) antipsychotics with a
prior 3-month washout period were identified (Table 1).
The study sample had a mean age of early 50s (atypical
vs. typical: 51.3 vs. 52.6, P = 0.081). More than half of the
patients in both cohorts were women (55.1% vs. 55.3%,
P = 0.950), while being retired was less common among










06 52.1 (11.8) 51.7 (11.7) 0.144 0.035
4 226 (56.5%) 224 (56.0%) 0.715 0.010
25 222 (55.5%) 228 (57.0%) 0.109 −0.030
2 18 (4.5%) 22 (5.5%) 0.541 −0.046
1 (0.3%) 1 (0.3%) 1.000 <0.001
3 1 (0.3%) 4 (1.0%) 0.375 −0.095
38 1 (0.3%) 3 (0.8%) 0.625 −0.071
5 2 (0.5%) 1 (0.3%) 1.000 0.041
6 14 (3.5%) 10 (2.5%) 0.481 0.059
0 1 (0.3%) 4 (1.0%) 0.375 −0.095
1 3 (0.8%) 2 (0.5%) 1.000 0.032
1 (0.3%) 0 (0.0%) 1.000 0.071
28 0.01 (0.07) 0.01 (0.07) 1.000 <0.001
9 0.08 (0.34) 0.05 (0.36) 0.298 0.071
29 4 (45) 3 (46) 0.287 0.021
and paired t-tests for matched samples; categorical variables were compared
sts for matched samples. P-values and standardized differences in bold indicates
-99) except sleep disorder, depression and anxiety disorder, which included
behavior, mental retardation, etc.
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nosed with mental comorbidities and patients treated
with concomitant medications among the two cohorts
were similar, except that the atypical cohort was less
likely to be treated with sedative hypnotics (1.4% vs.
3.5%, P = 0.018). Anxiolytics appeared to be the much
more commonly used (more than 11% for both cohorts)
than other kinds of concomitant medications (<5%).
With similar numbers of psychiatric-related outpatient
visits at baseline (0.17 vs. 0.22, P = 0.332), the atypical
cohort was associated with a lower frequency of hospi-
talizations (0.02 vs. 0.05, P = 0.028), which was further
associated with statistically significantly lower direct
medical costs ($20 vs. $42, P = 0.027). In the sensitivity
analysis, the propensity-score matching process selected







Use of antipsychotics [mean(SD)]
Days on of all antipsychotics 139.1 (109.0) 1
Time to all-cause discontinuation 111.0 (117.8) 1
Use of concomitant medication [n(%)]
Any use of anxiolytics 476 (73.5%) 4
Any use of anticholinergics 216 (33.3%) 3
Any use of antidepressants 147 (22.7%) 7
Any use of sedative-hypnotics 256 (39.5%) 1
Any use of mood stabilizers 78 (12.0%) 5
Medical resource utilization#
Any psychiatric hospitalization [n(%)] 297 (45.8%) 2
The number of psychiatric hospitalizations [mean(SD)] 1.65 (0.76) 1
Length of stay per hospitalization [mean(SD)] 85.6 (84.7) 9
Any psychiatric outpatient visit [n(%)] 519 (80.1%) 3
The number of psychiatric outpatient visits [mean(SD)] 7.95 (7.26) 6
Mental comorbidities
Mean number of mental comorbidities [mean(SD)] 0.72 (0.92) 0
Specific mental comorbidities## [n(%)]
Sleep disorder 131 (20.2%) 8
Unspecified mental disorder 112 (17.3%) 7
Depression 110 (17.0%) 5
Anxiety disorder 77 (11.9%) 3
Other psychotic disorder 35 (5.4%) 1
Continuous variables were compared using two-sample t-tests for unmatched samples
using chi-square tests for unmatched samples and McNemar’s tests for matched samp
# The number of psychiatric hospitalizations/length of stay per hospitalization was o
and the number of psychiatric outpatient visits was only for patients who had psyc
## Unspecified mental disorder (ICD-10: F99) corresponded to mental disorder whic
corresponded to any other mental disorders (ICD-10: F00-99) except sleep disorder,
dementia, mania, bipolar disorder, schizoaffective disorders, disorders of adult persowere the closest in propensity-score values to their
counterparts in the atypical cohort. After matching, the
two cohorts were comparable at baseline, and none of
the differences between the two cohorts remained statis-
tically significant both with regard to p-value and to
standardized difference.
Descriptive analyses of health care resource utilization
The descriptive statistics describing the health care
resource utilization and mental comorbidities achieved
by the atypical and typical cohorts over the 12-month
follow-up period are shown in Table 2. No statistically
significant differences in antipsychotic utilization were
found between the two cohorts, both in regard to adher-
ence and persistence. Antipsychotic medications were









43.7 (109.2) 0.483 143.2 (110.7) 143.9 (108.0) 0.938
10.2 (114.0) 0.910 113.2 (117.0) 109.0 (111.8) 0.606
12 (85.3%) <0.001 275 (68.8%) 342 (85.5%) <0.001
16 (65.4%) <0.001 143 (35.8%) 265 (66.3%) <0.001
8 (16.2%) 0.006 80 (20.0%) 57 (14.3%) 0.028
22 (25.3%) <0.001 163 (40.8%) 100 (25.0%) <0.001
2 (10.8%) 0.507 47 (11.8%) 42 (10.5%) 0.569
74 (56.7%) <0.001 192 (48.0%) 231 (57.8%) 0.002
.72 (0.81) 0.291 1.65 (0.76) 1.71 (0.83) 0.487
4.8 (84.2) 0.094 88.3 (86.9) 92.9 (82.9) 0.473
18 (65.8%) <0.001 310 (77.5%) 261 (65.3%) <0.001
.96 (6.25) 0.044 7.71 (6.89) 6.52 (5.70) 0.027
.54 (0.84) <0.001 0.64 (0.87) 0.49 (0.80) 0.012
4 (17.4%) 0.231 70 (17.5%) 63 (15.8%) 0.514
5 (15.5%) 0.432 63 (15.8%) 59 (14.8%) 0.700
2 (10.8%) 0.003 57 (14.3%) 39 (9.8%) 0.052
7 (7.7%) 0.020 42 (10.5%) 27 (6.8%) 0.063
3 (2.7%) 0.025 23 (5.8%) 7 (1.8%) 0.004
and paired t-tests for matched samples; categorical variables were compared
les. P-values in bold indicates statistical significance.
nly for patients who had psychiatric hospitalizations during follow-up period,
hiatric outpatient visits during follow-up period.
h was not otherwise specified across ICD-10: F00-98. Other psychotic disorder
unspecified mental disorder, depression and anxiety disorder, which included
nality and behavior, mental retardation, etc.
He et al. BMC Health Services Research  (2015) 15:149 Page 6 of 10in the typical group over the 12-month follow-up period,
and the mean time to medication discontinuation for
any cause among the two groups was 111.0 days and
110.2 days, respectively. Patients who received atypical
antipsychotics at the index date were significantly less
likely to use concomitant anxiolytic (73.5% vs. 85.3%,
P < 0.001) and anticholinergic medications (33.3% vs.
65.4%, P < 0.001), and were more likely to take antide-
pressants (22.7% vs. 16.2%, P = 0.006) and sedative-
hypnotics medications (39.5% vs. 25.3%, P < 0.001). In
terms of medical resource utilization, the atypical cohort
had a lower rate of psychiatric-related hospitalization
compared with the typical cohort (45.8% vs. 56.7%, P <
0.001), with a similar number of hospitalizations (1.65 vs.
1.72, P = 0.291) and length of stay per admission (85.6 vs.
94.8, P = 0.094) among inpatient users. In contrast, pa-
tients started with atypical medications had a statistically
significantly higher rate of psychiatric outpatient visits
(80.1% vs. 65.8%, P < 0.001) and a higher number of visits
among outpatient users (7.95 vs. 6.96, P = 0.044). Besides
that, the atypical cohort appeared to have a higher rate of
mental comorbidities across depression (17.0% vs. 10.8%,
P = 0.003), anxiety disorder (11.9% vs. 7.7%, P = 0.020) and
other psychotic disorders (5.4% vs. 2.7%, P = 0.025). The
study results did not change much when the sensitivity
analysis was conducted for the matched cohorts. Almost
all estimators of health care resource utilization exhibited
the same trend as in the core analysis. Compared to the
unmatched sample, there was no statistically significant
difference between atypical and typical cohorts for per-
centages of patients diagnosed with depression (14.3% vs.
9.8%, P = 0.052) or anxiety disorder (10.5% vs. 6.8%, P =
0.063) among the matched sample.
Descriptive analyses of direct medical costs
Table 3 presents the descriptive results of psychiatric-
related direct medical costs for study patients over the
12-month follow-up period. The atypical cohort had
significantly higher medication costs ($438 vs. $187, P <
0.001) compared with the typical cohort, and the differ-
ence was mainly attributable to antipsychotics ($288 vs.
$63, P < 0.001). As the result of much more outpatient
visits, the costs of outpatient services for the atypical
cohort were twice as much as the costs for the typical
cohort ($10 vs. $5, P < 0.001). However, compared with
the typical cohort, the mean annual non-medication
medical costs for the atypical cohort were significantly
lower ($1223 vs. $1704, P < 0.001), primarily driven by
the lower psychiatric related costs of inpatient services
($1213 vs. $1699, P < 0.001). Despite the significant dif-
ferences in almost all cost components, the unadjusted
mean direct medical costs for the two cohorts were sta-
tistically similar (atypical: $1661, typical: 1892; P =
0.100). As for the matched sample in the sensitivityanalysis, almost all costs components showed similar re-
sults to the core analysis, with the exception that the
costs difference for concomitant medications became
statistically insignificant ($61 vs. $40, P = 0.064). Consist-
ent with the results of the unmatched sample, the atyp-
ical matched cohort incurred lower total costs in
comparison with the typical matched cohort with a
statistically insignificant difference ($1711 vs. $1868,
P = 0.341).Multivariate analyses
Logistic regression results for medical and concomitant
pharmacy utilization are summarized in Table 4. Con-
trolling for baseline characteristics, we found that the
odds of being hospitalized during the follow-up period
among the atypical cohort were still significantly lower
than for the typical cohort (OR = 0.58, [95% CI, 0.44-
0.75], P < 0.001). With respect to outpatient services, the
atypical cohort was about twice as likely to have an out-
patient visit as the typical cohort (OR = 2.19, [95% CI,
1.64-2.93], P < 0.001). Consistent with the unadjusted re-
sults (Table 2), patients initiating atypical medications
were less likely to utilize concomitant anxiolytic (OR =
0.43, [95% CI, 0.31-0.60], P < 0.001) or anticholinergic
medications (OR = 0.24, [95% CI, 0.18-0.31], P < 0.001),
and were more likely to take antidepressants (OR = 1.64,
[95% CI, 1.18-2.28], P = 0.003) and sedative-hypnotic
medications (OR = 1.89, [95% CI, 1.45-2.46], P < 0.001).
All regression models that were based on matched
cohorts exhibited the same trend as the unmatched
sample.
Table 5 presents the marginal differences in OLS and
GLM models of total costs and costs by type of service.
Medication costs were significantly higher among the
atypical cohort than the typical cohort (marginal differ-
ences: $247 in OLS; $242 in GLM per patient), which
was mainly due to differences in the cost of anti-
psychotic medications (OLS: $217; GLM: $235). In terms
of medical costs, patients started with atypical antipsy-
chotics incurred statistically significant reduced costs of
inpatient services (OLS: −$476; GLM: −$569) and in-
creased costs of outpatient services (OLS: $5; GLM: $6).
In the sensitivity analysis, consistent with the unmatched
sample, the atypical matched cohort was associated with
statistically significant decreased medical costs (OLS: −
$399; GLM: −$450), which were more than enough to
offset the increased medication costs (OLS: $238; GLM:
$234). The total annual costs for the atypical cohort
were significantly lower than the typical cohort in the
GLM models (−$238, P = 0.031), while the differences
were not statistically significant in the OLS models
(−$229, P = 0.091) and regressions for the matched
cohort (OLS: −$161; GLM: −$150).
Table 3 Direct medical costs for atypical and typical cohorts during 12-month follow-up period (in 2009 US$)










Total costs 1661 (2224) 1892 (2465) −231 0.100 1711 (2240) 1868 (2450) −157 0.341
Medication costs 438 (626) 187 (337) 251 <0.001 409 (526) 172 (334) 237 <0.001
Antipsychotic medication 288 (431) 63 (216) 225 <0.001 268 (343) 64 (230) 204 <0.001
Concomitant medication 73 (266) 42 (98) 31 0.014 61 (194) 40 (99) 20 0.064
Other medication# 77 (197) 82 (213) −5 0.680 81 (207) 68 (189) 13 0.344
Medical costs 1223 (2058) 1704 (2344) −482 <0.001 1302 (2097) 1696 (2325) −394 0.011
Costs of inpatient services## 1213 (2061) 1699 (2346) −486 <0.001 1292 (2099) 1692 (2327) −399 0.010
Non-medication treatment costs 667 (1186) 992 (1443) −325 <0.001 716 (1223) 977 (1422) −262 0.005
Laboratory and diagnostic cost 254 (456) 388 (548) −134 <0.001 278 (477) 393 (546) −115 0.001
Other inpatient services 292 (539) 319 (476) −27 0.384 299 (516) 321 (482) −22 0.528
Costs of outpatient services 10 (28) 5 (26) 5 0.004 9 (25) 4 (11) 5 <0.001
Two-sample t-tests for unmatched samples and paired t-tests for matched samples. P-values in bold indicates statistical significance.
# Other medication corresponded to any other medication except antipsychotic and concomitant medication, which included antihypertension medication,
hypoglycemic medication, antibiotics, cardiovascular and cerebrovascular drugs, digestive system drugs, respiratory system drugs, antineoplastic drugs, etc.
## Non-medication treatment costs corresponded to the costs of any other treatment except medication, which included nursing, monitoring, psychotherapy,
behavior training and intervention, etc. Laboratory and diagnostic costs referred to the costs of physical examinations and biochemical tests. Costs of other
medical services included blood transfusion, medical consumable, air conditioning and heating fees.
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To our knowledge, this study is the first comprehensive,
retrospective comparison of the psychiatric-related
health care resource utilization and direct medical costs
for patients initiated with atypical or typical antipsy-
chotics in China. The results suggested that patients ini-
tiated with atypical antipsychotics were significantly less
likely to be hospitalized during follow-up period com-
pared to patients initiated with typical antipsychotics,
and less likely to use concomitant anxiolytic and anti-
cholinergic medications, even though they demonstrated
higher rates of mental comorbidities. As a result, the
atypical cohort was found to incur lower medical costs
relative to the typical cohort, which were sufficient to
offset their higher medication costs.Table 4 Regression-adjusted odds ratios on resource utilizatio
typical)
Variable Before matching N = 1131
OR 95% CI
Medical service
Any psychiatric hospitalization 0.58 0.44-0.75
Any psychiatric clinical visit 2.19 1.64-2.93
Use of concomitant medication
Any use of anxiolytics 0.43 0.31-0.60
Any use of anticholinergics 0.24 0.18-0.31
Any use of antidepressants 1.64 1.18-2.28
Any use of sedative-hypnotics 1.89 1.45-2.46
Any use of mood stabilizers 1.11 0.75-1.64
Logistic regressions adjusted for baseline characteristics including demographics (a
resource utilization and costs during baseline. Bold type indicates statistical significPsychiatric-related hospitalization is often the conse-
quence of a relapse or exacerbation of psychosis for
patients with schizophrenia [28]. Consistent with some
previous studies, a lower rate of psychiatric-related hos-
pitalizations was observed among patients initiated with
atypical medications in the present study, despite both
cohorts displaying similar levels of medication adherence
[29,30]. Our study may provide some evidence for the
superiority of atypical antipsychotics in terms of redu-
cing psychiatric hospitalizations, suggesting that they
may have better efficacy and/or fewer or better tolerated
side effects. Unlike inpatient services, the number of
outpatient visits for the atypical cohort was significantly
higher than the typical cohort. These results are similar
to previous findings reported in the literature showingn between atypical and typical cohort (atypical vs.
After matching N = 800
p-value OR 95% CI p-value
<0.001 0.66 0.49-0.89 0.006
<0.001 1.81 1.32-2.50 <0.001
<0.001 0.37 0.26-0.53 <0.001
<0.001 0.26 0.19-0.35 <0.001
0.003 1.49 1.01-2.20 0.044
<0.001 2.11 1.55-2.88 <0.001
0.605 1.09 0.69-1.72 0.706
ge, gender and retired), mental comorbidities, concomitant medication, prior
ance.
Table 5 Regression-adjusted cost differences during 12-month follow-up period between atypical and typical cohort
(atypical vs. typical)
Variable Before matching N = 1131 After matching N = 800
OLS GLM OLS GLM
Diff p-value Diff p-value Diff p-value Diff p-value
Total costs −229 0.091 −238 0.031 −161 0.329 −150 0.245
Medication costs 247 <0.001 242 <0.001 238 <0.001 234 <0.001
Antipsychotic medication 217 <0.001 235 <0.001 204 <0.001 229 <0.001
Concomitant medication 30 0.016 22 <0.001 21 0.052 16 <0.001
Other medication# 1 0.959 7 0.190 12 0.392 15 0.005
Medical costs −476 <0.001 −569 <0.001 −399 0.011 −450 <0.001
Costs of inpatient services## −481 <0.001 −592 <0.001 −404 0.010 −555 <0.001
Non-medication treatment cost −315 <0.001 −401 <0.001 −269 0.004 −351 <0.001
Laboratory and diagnostic cost −136 <0.001 −158 <0.001 −113 0.002 −131 <0.001
Other inpatient services −30 0.324 −39 0.056 −22 0.532 −29 0.229
Costs of outpatient services 5 0.002 6 <0.001 5 <0.001 5 <0.001
Regressions adjusted for baseline characteristics including demographics (age, gender and retired), mental comorbidities, concomitant medication, prior resource
utilization and costs during baseline. Bold type indicates statistical significance.
# Other medication corresponded to any other medication except antipsychotic and concomitant medication, which included antihypertension medication,
hypoglycemic medication, antibiotics, cardiovascular and cerebrovascular drugs, digestive system drugs, respiratory system drugs, antineoplastic drugs, etc.
## Non-medication treatment costs corresponded to the costs of any other treatment except medication, which included nursing, monitoring, psychotherapy, be-
havior training and intervention, etc. Laboratory and diagnostic costs referred to the costs of physical examinations and biochemical tests. Costs of other medical
services included blood transfusion, medical consumable, air conditioning and heating fees.
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source utilization in outpatient care, which may indicate
closer interactions between patients and psychiatrists
and further lead to better adherence and lower relapse
rates [31,32].
Overall the rates of antipsychotic medication persist-
ence observed in this study were low, with a mean time
to medication discontinuation for any cause among two
groups of 111.0 days and 110.2 days, respectively, and
approximately half the rate as that seen in similar natur-
alistic studies from the US [33,34]. This finding warrants
further examination of the antipsychotic treatment pat-
terns of patients with schizophrenia in China. Time to
all-cause treatment discontinuation is considered a com-
posite proxy measure of treatment efficacy, safety, and
tolerability, and strategies to improve medication persist-
ence have been shown to have the potential to improve
patient outcomes [35].
Concomitant medications were widely used in our
sample. Nearly 90% of patients received some kinds of
psychiatric-related concomitant medications, which were
similar with the findings from Nielsen et al. [36]. Anxio-
lytic medications were the most commonly prescribed
concomitant medication among the two cohorts. They
were prescribed less often in the atypical cohort despite
a higher prevalence of anxiety disorders, which may con-
firm that atypical antipsychotics may be more effective
than typical ones in controlling anxiety disorders [37,38].
The atypical cohort also, as expected, received signifi-
cantly fewer anticholinergic medications, which mayfurther support the lower risk of extrapyramidal side ef-
fects associated with this class of medications in clinical
settings [13,39]. However, patients initiating atypical an-
tipsychotics were significantly more likely to take antide-
pressants and sedative-hypnotics medications than the
typical cohort. That partially could be the result of a
high prevalence of mental comorbidities such as depres-
sion and sleep disorders in the atypical cohort.
Our results are consistent with the findings from pre-
vious studies that found that the use of atypical antipsy-
chotics was associated with increased medication costs
and decreased medical costs [29,40]. Both the descriptive
and multivariate analyses showed that the higher medi-
cation acquisition costs among patients initiated with
atypical antipsychotics were sufficiently offset by their
lower medical costs, which is consistent with the find-
ings of a study from Taiwan [29]. The results were con-
firmed by the sensitivity analysis after propensity-score
matching, which suggests that the study results are rela-
tively robust.
The results of this study need to be interpreted with
care. Firstly, this study used claims data from the
UEBMI insurance database, which includes both people
who are employed and those who are retired. Individuals
in this system may not reflect persons utilizing services
in other systems of care. As such, these results may not
be generalizable to the whole population with schizo-
phrenia in Tianjin, China. Secondly, insurance claims
data do not provide detailed patient-level information on
clinical symptoms and disease severity. Although the
He et al. BMC Health Services Research  (2015) 15:149 Page 9 of 10results after propensity-score matching are similar to the
unmatched results, unobserved confounders (e.g., severity
of illness) may potentially affect the results. Thirdly, all
atypical antipsychotics were considered as a homogenous
group of drugs in our study, as were all typical antipsy-
chotics. In reality, there are differences in the efficacy,
effectiveness, and adverse-effect profiles between indi-
vidual drugs within the same group [41,42]. Lastly, the
12-month follow-up period may not be long enough to
observe changes in costs and outcomes with a chronic
illness like schizophrenia. Studies with a longer-term
follow-up period may be warranted.
Conclusions
The present study estimated and compared the psychiatric-
related health care resource utilization and direct medical
costs associated with the initial prescription with atypical
antipsychotics compared with typical antipsychotics in the
treatment of schizophrenia in patients from Tianjin, China.
Medication costs were higher for patients initiated with
atypical antipsychotics during the 12-month follow-up.
However, the atypical cohort was less likely to be hospital-
ized compared to the typical cohort, which in turn led to
decreased medical costs. Initiation with atypical antipsy-
chotics for patients with schizophrenia did not appear to in-
crease the use of health care services as a whole, and it was
associated with a reduction in medical costs that was suffi-
cient to offset the higher medication costs for the atypical
antipsychotics.
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